67-6

27/93

1) Bloem BR, Okun MS, Klein C: Parkinson’s disease. Lancet 2021 doi: 10.1016/S0140-6736(21)00218-X [published Online First: 2021/04/14] 2) Calabresi P, Di Filippo M, Ghiglieri V, et al: Levodo-pa-induced dyskinesias in patients with Parkinson’s disease: filling the bench-to-bedside gap. Lancet Neurol. 2010; 9: 1106-17. doi: 10.1016/S1474-4422(10)70218-0 [published Online First: 2010/10/01] 3) Kalia LV, Lang AE: Parkinson’s disease. Lancet. 2015; 386: 896-912. doi: 10.1016/S0140-6736(14)61393-3 4) Hatano T, Kubo SI, Shimo Y, et al: Unmet needs of patients with Parkinson’s disease: interview survey of patients and caregivers. J Int Med Res. 2009; 37: 717- 26. doi: 10.1177/147323000903700315 [published Online First: 2009/07/11] 5) Spillantini MG, Schmidt ML, Lee VM, et al: Alpha-sy-nuclein in Lewy bodies. Nature. 1997; 388: 839-40. doi: 10.1038/42166 [published Online First: 1997/08/28] 6) Polymeropoulos MH, Lavedan C, Leroy E, et al: Muta-tion in the alpha-synuclein gene identified in families with Parkinson’s disease. Science. 1997; 276: 2045-7. [published Online First: 1997/06/27] 7) Kruger R, Kuhn W, Muller T, et al: Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat Genet. 1998; 18: 106-8. doi: 10.1038/ng0298-106 [published Online First: 1998/02/14] 8) Zarranz JJ, Alegre J, Gomez-Esteban JC, et al: The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004; 55: 164-73. doi: 10.1002/ana.10795 [published Online First: 2004/ 02/03] 9) Appel-Cresswell S, Vilarino-Guell C, Encarnacion M, et al: Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson’s disease. Mov Disord. 2013; 28: 811-3. doi: 10.1002/mds.25421 [published Online First: 2013/03/05]10) Proukakis C, Dudzik CG, Brier T, et al: A novel alpha- synuclein missense mutation in Parkinson disease. Neurology. 2013; 80: 1062-4. doi: 10.1212/WNL.0b013e 31828727ba [published Online First: 2013/02/22]11) Lesage S, Anheim M, Letournel F, et al: G51D alpha-sy-nuclein mutation causes a novel parkinsonian-pyra-midal syndrome. Ann Neurol. 2013; 73: 459-71. doi: 10.1002/ana.23894 [published Online First: 2013/03/26]12) Walker LC, Jucker M: Neurodegenerative diseases: expanding the prion concept. Annu Rev Neurosci. 2015; 38: 87-103. doi: 10.1146/annurev-neuro-071714- 033828 [published Online First: 2015/04/04]13) Stopschinski BE, Diamond MI: The prion model for progression and diversity of neurodegenerative diseases. Lancet Neurol. 2017; 16: 323-32. doi: 10.1016/S1474-4422(17)30037-6 [published Online First: 2017/02/28]14) Dickson DW, Braak H, Duda JE, et al: Neuropatholog-ical assessment of Parkinson’s disease: refining the diagnostic criteria. Lancet Neurol. 2009; 8: 1150-7. doi: 10.1016/S1474-4422(09)70238-815) Wakabayashi K, Tanji K, Odagiri S, et al: The Lewy body in Parkinson’s disease and related neurodegener-ative disorders. Mol Neurobiol. 2013; 47: 495-508. doi: 10.1007/s12035-012-8280-y [published Online First: 2012/05/25]16) Tanaka K, Suzuki T, Hattori N, et al: Ubiquitin, prote-asome and parkin. Biochim Biophys Acta. 2004; 1695: 235-47. doi: 10.1016/j.bbamcr.2004.09.026 [published Online First: 2004/12/02]17) Shahmoradian SH, Lewis AJ, Genoud C, et al: Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes. Nat Neurosci. 2019; 22: 1099-109. doi: 10.1038/s41593-019-0423-2 [published Online First: 2019/06/27]18) Burre J, Sharma M, Sudhof TC: Cell Biology and Pathophysiology of alpha-Synuclein. Cold Spring Harb Perspect Med. 2018; 8. doi: 10.1101/cshperspect.a024091 [published Online First: 2017/01/22]19) Auluck PK, Caraveo G, Lindquist S: alpha-Synuclein: membrane interactions and toxicity in Parkinson’s disease. Annu Rev Cell Dev Biol. 2010; 26: 211-33. doi: 10.1146/annurev.cellbio.042308.113313 [published Online First: 2010/05/27]20) Yoshino H, Tomiyama H, Tachibana N, et al: Pheno-typic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism. Neurology 2010; 75: 1356-61. doi: 10.1212/WNL.0b013e3181f73649 [published Online First: 2010/10/13]21) Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R: Mutations in the glucocerebrosidase gene and Parkin-son’s disease in Ashkenazi Jews. N Engl J Med. 2004; 351: 1972-7. doi: 10.1056/NEJMoa033277 [published Online First: 2004/11/05]22) Sidransky E, Nalls MA, Aasly JO, et al: Multicenter analysis of glucocerebrosidase mutations in Parkin-son’s disease. N Engl J Med. 2009; 361: 1651-61. doi: 10. 1056/NEJMoa0901281 [published Online First: 2009/ 10/23]23) Lee JS, Kanai K, Suzuki M, et al: Arylsulfatase A, a genetic modifier of Parkinson’s disease, is an alpha-sy-nuclein chaperone. Brain. 2019; 142: 2845-59. doi: 10.1093/ brain/awz205 [published Online First: 2019/07/18]24) Gan-Or Z, Ozelius LJ, Bar-Shira A, et al: The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease. Neurology. 2013; 80: 1606-10. doi: 10.1212/WNL.0b013e31828f180e [published Online First: 2013/03/29]25) Oji Y, Hatano T, Ueno SI, et al: Variants in saposin D domain of prosaposin gene linked to Parkinson’s disease. Brain. 2020; 143: 1190-205. doi: 10.1093/brain/awaa064 [published Online First: 2020/03/24]26) Burke JE, Dennis EA: Phospholipase A2 biochemistry. Cardiovasc Drugs Ther. 2009; 23: 49-59. doi: 10.1007/s10557-008-6132-9 [published Online First: 2008/10/22]27) Morgan NV, Westaway SK, Morton JE, et al: PLA2G6, encoding a phospholipase A2, is mutated in neurode-generative disorders with high brain iron. Nat Genet. 2006; 38: 752-4. doi: 10.1038/ng1826 [published Online First: 2006/06/20]28) Paisan-Ruiz C, Bhatia KP, Li A, et al: Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann 535Author contributionTH contributed to the conception, drafting the paper, preparing the figure, and obtaining grants.Conflict of interest statementThe author declares that there are no conflicts of interest.References